Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Bethesda

Sponsor
Mirati

Protocol Number
Mirati 265-109

To Learn More Call
201-510-0910